AbbVie Inc. (NYSE:ABBV) Shares Acquired by Linden Thomas Advisory Services LLC

Linden Thomas Advisory Services LLC grew its position in AbbVie Inc. (NYSE:ABBV) by 1.0% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 12,463 shares of the company’s stock after acquiring an additional 121 shares during the period. Linden Thomas Advisory Services LLC’s holdings in AbbVie were worth $1,931,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of ABBV. Parkside Financial Bank & Trust increased its stake in shares of AbbVie by 31.9% during the fourth quarter. Parkside Financial Bank & Trust now owns 15,298 shares of the company’s stock worth $2,371,000 after purchasing an additional 3,698 shares in the last quarter. Marks Group Wealth Management Inc increased its stake in shares of AbbVie by 2.9% during the fourth quarter. Marks Group Wealth Management Inc now owns 2,254 shares of the company’s stock worth $349,000 after purchasing an additional 63 shares in the last quarter. Roble Belko & Company Inc increased its stake in shares of AbbVie by 45.8% during the fourth quarter. Roble Belko & Company Inc now owns 592 shares of the company’s stock worth $92,000 after purchasing an additional 186 shares in the last quarter. Larson Financial Group LLC increased its stake in shares of AbbVie by 12.1% during the fourth quarter. Larson Financial Group LLC now owns 2,835 shares of the company’s stock worth $439,000 after purchasing an additional 305 shares in the last quarter. Finally, Illinois Municipal Retirement Fund increased its stake in shares of AbbVie by 16.5% during the fourth quarter. Illinois Municipal Retirement Fund now owns 186,405 shares of the company’s stock worth $28,887,000 after purchasing an additional 26,419 shares in the last quarter. Institutional investors and hedge funds own 70.23% of the company’s stock.

Insiders Place Their Bets

In other AbbVie news, EVP Nicholas Donoghoe sold 21,082 shares of the stock in a transaction that occurred on Wednesday, March 20th. The shares were sold at an average price of $176.30, for a total transaction of $3,716,756.60. Following the sale, the executive vice president now directly owns 55,903 shares in the company, valued at approximately $9,855,698.90. The transaction was disclosed in a document filed with the SEC, which is available through this link. In other AbbVie news, EVP Nicholas Donoghoe sold 21,082 shares of the stock in a transaction that occurred on Wednesday, March 20th. The shares were sold at an average price of $176.30, for a total transaction of $3,716,756.60. Following the sale, the executive vice president now directly owns 55,903 shares in the company, valued at approximately $9,855,698.90. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, EVP Jeffrey Ryan Stewart sold 58,949 shares of the stock in a transaction that occurred on Monday, March 18th. The stock was sold at an average price of $178.79, for a total transaction of $10,539,491.71. Following the sale, the executive vice president now owns 60,941 shares in the company, valued at $10,895,641.39. The disclosure for this sale can be found here. Insiders have sold a total of 383,324 shares of company stock worth $67,780,003 in the last ninety days. 0.25% of the stock is owned by corporate insiders.

AbbVie Trading Up 0.8 %

Shares of ABBV stock traded up $1.42 during trading hours on Tuesday, hitting $169.31. The company had a trading volume of 2,766,998 shares, compared to its average volume of 5,596,262. The company’s fifty day moving average is $175.34 and its 200 day moving average is $160.42. The company has a debt-to-equity ratio of 5.02, a current ratio of 0.87 and a quick ratio of 0.76. AbbVie Inc. has a fifty-two week low of $130.96 and a fifty-two week high of $182.89. The stock has a market capitalization of $299.79 billion, a PE ratio of 62.21, a price-to-earnings-growth ratio of 2.14 and a beta of 0.58.

AbbVie (NYSE:ABBV) last issued its quarterly earnings data on Friday, February 2nd. The company reported $2.79 EPS for the quarter, topping the consensus estimate of $2.76 by $0.03. AbbVie had a net margin of 8.95% and a return on equity of 162.28%. The firm had revenue of $14.30 billion for the quarter, compared to analyst estimates of $14.02 billion. During the same period in the prior year, the business posted $3.60 EPS. The business’s revenue for the quarter was down 5.4% compared to the same quarter last year. Research analysts expect that AbbVie Inc. will post 11.16 earnings per share for the current fiscal year.

AbbVie Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 15th. Stockholders of record on Monday, April 15th will be issued a $1.55 dividend. The ex-dividend date is Friday, April 12th. This represents a $6.20 annualized dividend and a dividend yield of 3.66%. AbbVie’s dividend payout ratio is currently 227.11%.

Analysts Set New Price Targets

Several analysts recently issued reports on ABBV shares. Raymond James upped their price objective on shares of AbbVie from $181.00 to $189.00 and gave the company an “outperform” rating in a research note on Monday, February 5th. Barclays upped their price objective on shares of AbbVie from $185.00 to $195.00 and gave the company an “overweight” rating in a research note on Wednesday, March 27th. Guggenheim upped their price objective on shares of AbbVie from $188.00 to $190.00 and gave the company a “buy” rating in a research note on Friday, March 22nd. William Blair raised shares of AbbVie from a “market perform” rating to an “outperform” rating in a research note on Monday, January 29th. Finally, Truist Financial upped their price objective on shares of AbbVie from $180.00 to $195.00 and gave the company a “buy” rating in a research note on Tuesday, February 6th. Three analysts have rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $177.43.

AbbVie Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.